Athira Pharma Inc
NASDAQ:ATHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Ossur hf
CSE:OSSR
|
IS |
Athira Pharma Inc
Total Equity
Athira Pharma Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Athira Pharma Inc
NASDAQ:ATHA
|
Total Equity
$44.8m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$81.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$18.5B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$86.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$52.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$26.5B
|
CAGR 3-Years
36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
6%
|
|
Athira Pharma Inc
Glance View
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 63 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and stop neurodegeneration. Its pipeline consists of both blood brain barrier (BBB) permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system (PNS), and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. The company is also advancing potential drug candidates for neuropathic pain, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. Its neuropathic pain drug candidate, ATH-1020, completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
See Also
What is Athira Pharma Inc's Total Equity?
Total Equity
44.8m
USD
Based on the financial report for Dec 31, 2024, Athira Pharma Inc's Total Equity amounts to 44.8m USD.
What is Athira Pharma Inc's Total Equity growth rate?
Total Equity CAGR 3Y
-48%
Over the last year, the Total Equity growth was -66%. The average annual Total Equity growth rates for Athira Pharma Inc have been -48% over the past three years .
